Harrow (NASDAQ:HROW) Stock Price Up 5% – Time to Buy?

Harrow, Inc. (NASDAQ:HROW)’s share price was up 5% during trading on Friday. The stock traded as high as $29.14 and last traded at $29.7020. 27,980 shares traded hands during trading, a decline of 96% from the average session volume of 695,777 shares. The stock had previously closed at $28.30.

Key Headlines Impacting Harrow

These are some of the HROW headlines that stood out recently:

• Positive Sentiment: An article contends HROW still looks undervalued despite a reported 229% gain over three years, potentially reinforcing a bullish view of its longer-term prospects. Harrow stock still looks undervalued
• Neutral Sentiment: Harrow management plans to meet investors at the Craig-Hallum Alpha Select Conference on Nov. 17 and present at the Jefferies Global Healthcare Conference on Nov. 18. The events offer investor access, but no new business or financial results were announced. Harrow investor conference announcement
• Negative Sentiment: HC Wainwright reduced its FY2027 EPS estimate to $0.50 from $0.88, and cut its forecasts for Q3 2027 to $0.32 from $0.40 and Q4 2027 to $0.92 from $1.07. These downward revisions point to lower expected earnings in those periods. Harrow analyst estimate report

Wall Street Analysts Forecast Growth

HROW has been the topic of a number of research reports. Leerink Partners started coverage on shares of Harrow in a research note on Wednesday, September 9th. They issued an “outperform” rating and a $45.00 price target on the stock. Zacks Research cut Harrow from a “hold” rating to a “strong sell” rating in a research report on Tuesday, November 3rd. BTIG Research restated a “buy” rating and issued a $63.00 target price on shares of Harrow in a research note on Wednesday. Weiss Ratings restated a “sell (e+)” rating on shares of Harrow in a research note on Friday, October 16th. Finally, Wall Street Zen raised Harrow from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $66.20.

Harrow Stock Up 7.8%

The company has a current ratio of 2.29, a quick ratio of 2.08 and a debt-to-equity ratio of 10.15. The business’s fifty day moving average price is $30.94 and its two-hundred day moving average price is $37.59. The firm has a market cap of $1.15 billion, a P/E ratio of -39.07 and a beta of 0.18.

Harrow (NASDAQ:HROW) last issued its quarterly earnings data on Monday, November 9th. The company reported $0.25 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.19 by $0.06. The firm had revenue of $99.30 million during the quarter, compared to analysts’ expectations of $98.59 million. Harrow had a negative net margin of 9.39% and a negative return on equity of 69.81%. As a group, equities research analysts anticipate that Harrow, Inc. will post -0.02 EPS for the current year.

Institutional Trading of Harrow

A number of institutional investors and hedge funds have recently made changes to their positions in HROW. KBC Group NV acquired a new position in shares of Harrow during the 1st quarter valued at about $31,000. Sterling Capital Management LLC raised its stake in shares of Harrow by 836.8% in the 3rd quarter. Sterling Capital Management LLC now owns 1,068 shares of the company’s stock valued at $33,000 after acquiring an additional 954 shares in the last quarter. First Bancorp Inc ME bought a new position in shares of Harrow in the 2nd quarter valued at approximately $64,000. State of Wyoming acquired a new stake in Harrow in the 2nd quarter worth approximately $72,000. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new stake in Harrow in the 3rd quarter worth approximately $59,000. Institutional investors and hedge funds own 72.76% of the company’s stock.

Harrow Company Profile

Harrow is a pharmaceutical company focused on developing, acquiring and commercializing treatments for eye conditions. Its portfolio includes prescription ophthalmic medicines used in areas such as dry eye disease, eye inflammation and pain management, as well as products used in eye surgery and clinical settings. The company markets branded products including VEVYE, a treatment for dry eye disease, and IHEEZO, an ophthalmic anesthetic gel. Through its ImprimisRx subsidiary, Harrow also provides compounded medications and related services for ophthalmology practices and patients.